KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Emergent BioSolutions (EBS) EPS (Weighted Average and Diluted) (2016 - 2026)

Emergent BioSolutions has reported EPS (Weighted Average and Diluted) over the past 17 years, most recently at $0.07 for Q1 2026.

  • For Q1 2026, EPS (Weighted Average and Diluted) fell 94.12% year-over-year to $0.07; the TTM value through Mar 2026 reached -$0.2, up 92.59%, while the annual FY2025 figure was $0.93, 125.83% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q1 2026 was $0.07 at Emergent BioSolutions, up from -$0.96 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $2.06 in Q3 2024 and troughed at -$5.38 in Q2 2024.
  • A 5-year average of -$1.28 and a median of -$0.88 in 2023 define the central range for EPS (Weighted Average and Diluted).
  • Biggest five-year swings in EPS (Weighted Average and Diluted): crashed 10500.0% in 2022 and later surged 600.0% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$1.34 in 2022, then surged by 34.33% to -$0.88 in 2023, then soared by 35.23% to -$0.57 in 2024, then plummeted by 68.42% to -$0.96 in 2025, then skyrocketed by 107.29% to $0.07 in 2026.
  • Business Quant data shows EPS (Weighted Average and Diluted) for EBS at $0.07 in Q1 2026, -$0.96 in Q4 2025, and $0.91 in Q3 2025.